Back

Levosimendan administration and survival in patients receiving mechanical circulatory support: insights from an unselected real-world cohort

29 August 2026 (10:55 - 11:05)
Organised by: Logo
Congress Presentation Part of: From myocardial injury to remodelling: new biomarkers and therapeutic windows Cardiogenic Shock ESC Professional Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Mr Emre Ozdemircelik

(Germany)

5 More presentations in this session

Presentation thumbnail
Peak high-sensitivity troponin-T concentration and risk of heart failure in patients with suspected acute coronary syndrome
Doctor P. Ahle Erichsen (Gentofte, DK)
Abstract Slides Video
Presentation thumbnail
Endomyocardial biopsy-based inflammatory phenotypes predict outcomes in virus-negative inflammatory cardiomyopathy
Doctor C. Baumeier (Berlin, DE)
Abstract Slides Video
Presentation thumbnail
A newborn screening–enabled therapeutic window in late-onset fabry disease: long-term divergent remodeling trajectories with early-stage treatment
Doctor K. Sung (Taipei, TW)
Abstract Slides Video
Presentation thumbnail
Low QRS voltages and risk stratification in acute myocarditis : insights from the AMPHIBIA registry
Mr F. Ravera (Paris, FR)
Abstract Slides Video
Presentation thumbnail
Titin expression in peripheral monocytes as a biomarker of left ventricular dysfunction in acute myocarditis.
Doctor S. Maragkoudakis (Chania, GR)
Abstract Slides Video

Access the full session

Session thumbnail
From myocardial injury to remodelling: new biomarkers and therapeutic windows
Video

The Event

Event poster

ESC Congress 2026

29 August 2026 10:55 CET
You may be interested in
thumbnail
Congress Session
Hot research in cardiogenic shock management
11 May 2024
thumbnail
Congress Presentation
Should we use levosimendan?
20 March 2026
thumbnail
Congress Presentation
The experience of more than three hundred levosimendan administrations: what we have learned
29 August 2025
thumbnail
Congress Session
Progress in advanced heart failure therapy
30 August 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources